Moderna

Moderna develops mRNA-based therapeutics and vaccines, having demonstrated the platform's potential through its COVID-19 vaccine and now expanding into oncology, rare diseases, and respiratory viruses with a pipeline of over 40 programs. The company's engineering challenges include building digital infrastructure for mRNA sequence design and optimization, developing manufacturing execution systems for complex biological production processes, and creating data platforms that integrate clinical trial data with genomic and immunological datasets. Their technology organization supports both the computational biology workflows that design mRNA sequences and the enterprise systems required for a rapidly scaling commercial pharmaceutical operation. Moderna's hiring patterns reflect the company's evolution from pandemic-era rapid deployment to a diversified therapeutics platform, with growing demand for software engineers, data scientists, and ML engineers who can accelerate the mRNA development cycle.